US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Organon & Co.

< Previous 1 2 3 Next >
News headline image
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Announces Quarterly Dividend
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon to Present New Research on Access and Value at ISPOR 2026
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the First Quarter Ended March 31, 2026
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Cancels First Quarter Earnings Call
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Sun Pharma signs Definitive Agreement to Acquire Organon
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Completes Divestiture of JADA® System to Laborie
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Third Quarter Ended September 30, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Second Quarter Ended June 30, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 3 Next >